Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD

2.63  -0.1 (-3.66%)

Fundamental Rating

2

Overall SANA gets a fundamental rating of 2 out of 10. We evaluated SANA against 572 industry peers in the Biotechnology industry. The financial health of SANA is average, but there are quite some concerns on its profitability. SANA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SANA had negative earnings in the past year.
SANA had a negative operating cash flow in the past year.
SANA had negative earnings in each of the past 5 years.
In the past 5 years SANA always reported negative operating cash flow.
SANA Yearly Net Income VS EBIT VS OCF VS FCFSANA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

SANA has a Return On Assets of -54.67%. This is comparable to the rest of the industry: SANA outperforms 44.42% of its industry peers.
SANA has a Return On Equity of -104.56%. This is comparable to the rest of the industry: SANA outperforms 45.31% of its industry peers.
Industry RankSector Rank
ROA -54.67%
ROE -104.56%
ROIC N/A
ROA(3y)-38.13%
ROA(5y)-36.99%
ROE(3y)-67.12%
ROE(5y)-63.01%
ROIC(3y)N/A
ROIC(5y)N/A
SANA Yearly ROA, ROE, ROICSANA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

SANA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SANA Yearly Profit, Operating, Gross MarginsSANA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

SANA has more shares outstanding than it did 1 year ago.
SANA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SANA Yearly Shares OutstandingSANA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M
SANA Yearly Total Debt VS Total AssetsSANA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -4.01, we must say that SANA is in the distress zone and has some risk of bankruptcy.
SANA has a Altman-Z score (-4.01) which is in line with its industry peers.
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.01
ROIC/WACCN/A
WACCN/A
SANA Yearly LT Debt VS Equity VS FCFSANA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

SANA has a Current Ratio of 4.47. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.47, SANA is in line with its industry, outperforming 50.09% of the companies in the same industry.
A Quick Ratio of 4.47 indicates that SANA has no problem at all paying its short term obligations.
With a Quick ratio value of 4.47, SANA perfoms like the industry average, outperforming 51.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
SANA Yearly Current Assets VS Current LiabilitesSANA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

SANA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.45%.
EPS 1Y (TTM)1.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1350%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SANA will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.08%
EPS Next 2Y16.95%
EPS Next 3Y10.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SANA Yearly Revenue VS EstimatesSANA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
SANA Yearly EPS VS EstimatesSANA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SANA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANA Price Earnings VS Forward Price EarningsSANA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SANA Per share dataSANA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.95%
EPS Next 3Y10.05%

More info and screens

0

5. Dividend

5.1 Amount

SANA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (2/11/2025, 11:53:40 AM)

2.63

-0.1 (-3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners90.41%
Inst Owner Change-62.95%
Ins Owners8.62%
Ins Owner Change-1.28%
Market Cap587.20M
Analysts81.54
Price Target10.71 (307.22%)
Short Float %24.72%
Short Ratio6.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.8%
Min EPS beat(2)1.83%
Max EPS beat(2)27.76%
EPS beat(4)2
Avg EPS beat(4)-6.81%
Min EPS beat(4)-51.07%
Max EPS beat(4)27.76%
EPS beat(8)5
Avg EPS beat(8)9.36%
EPS beat(12)8
Avg EPS beat(12)9.4%
EPS beat(16)11
Avg EPS beat(16)-27.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5%
PT rev (3m)-21.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.01
P/tB 6.34
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0
BVpS1.31
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.67%
ROE -104.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.13%
ROA(5y)-36.99%
ROE(3y)-67.12%
ROE(5y)-63.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 204.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -4.01
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)161.63%
Cap/Depr(5y)463.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1350%
EPS Next Y12.08%
EPS Next 2Y16.95%
EPS Next 3Y10.05%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.72%
EBIT Next 3Y7.38%
EBIT Next 5YN/A
FCF growth 1Y20.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.66%
OCF growth 3YN/A
OCF growth 5YN/A